Expertise and the utilization of Next Generation Sequencing techniques, bioinformatics, and data analysis in relation to communicable diseases, in terms of diagnostic approaches within the research and development sectors. These sectors include both practices in virology and bacteriology, including studies related to Mycobacterium tuberculosis, inclusive of Mycobacteria other than tuberculosis, influenza, HIV, RSV.
Encompasses a spectrum of conditions that are significant of the relationship/association between cardiovascular health and metabolic processes. Significance to diabetes, type 2 diabetes, obesity, cardiovascular disease (including hypertension, dyslipidemia, atherosclerosis and heart failure). Through the concept of GWAS (Genome wide association studies, to detect SNPs, single nucleotide polymorphisms), inclusive of genetic predisposition and epigenetic analysis, to ascertain who would ideally benefit from targeted therapies
The primary investigation of epigenetics (histone modifications, methylation, phosphorylation, ubiquitination) in various categories, namely celiac disease, Rheumatoid arthritis, type I diabetes, Behcet's syndrome, systemic lupus erythematosus
Utilizing various platforms for genomic analysis, most notably Whole Exome Sequencing, Transcriptomics, Targeted sequencing and Chromosomal Microarrays.
Neuroepigenomics is translating discoveries into precision medicine, most notably in the following sectors, namely Parkinsons, Huntington's Disease, frontotemporal dementia, chronic traumatic encephalopathy (CTE), Lewy body dementia and limbic predominant age-related TDP-43 encephalopathy (LATE). Additionally, multiple sclerosis (MS) and neuromyelitis optical spectrum disorder (NMOSD), amyotrophic lateral sclerosis (ALS, often known as “Lou Gehrig's disease”) and progressive supranuclear palsy (PSP), inclusive of Creutzfeldt-Jakob disease
Director/CEO
"Servant Leader, Geneticist and Clinical Trialist. With over 17 years of experience as a medical scientist. Therapeutic areas of interest and expertise, emphasis on both communicable and non-communicable diseases, most notably oncology, tuberculosis (in association with HIV), and COVID-19. Integral membership in the Human Genome Organization (HUGO- International, headquartered in Farmington, USA) too, as part of my many accolades. In addition, a Senior Fellowship Member at the United Nations Artificial Intelligence Forum For Developing Nations, headquartered in Geneva, Switzerland. Oncogenexe Biotech prides itself on a multi- faceted approach to Therapeutic Development, Research and Development, inclusive of utilizing various platforms pertaining to Data Analysis
Creating targeted treatments designed to improve patient outcomes and quality of life
Oncogenexe Biotech’s Clinical Trials service supports the design and execution of oncology-focused studies to evaluate safety, efficacy, and patient outcomes. Protocol_ PDAC_0_001 A multicentre open labelled randomized phase I dose escalation and expansion trial evaluating the safetyefficacy of a Bispecific/Trispecific Antibody Drug Conjugate (novel design), dosage formulation, Pharmacokinetic/Pharmacodynamic PK/PD analysis, safety evaluation and tolerability, and recommended Phase 2 dose, in participants stricken with Pancreatic Ductal Adenocarcinoma (PDAC), evaluating 3 pathways, the NFκB//NUAK1 (canonical, non-canonical), and the Phospho-inisotide Epidermal Growth Factor Receptor/Phospho-inisotide 3 Kinase, EGFR/PI3K/AKT/mTOR pathways
Providing comprehensive care and resources to patients during their treatment journey.
Specifically designed for aspiring molecular biology affiliated medical scientists and doctors (in the genetics, microbiology and biochemistry fields)



